Extracellular Vesicle Coating with Fc Binding Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The loading of large and complex protein biologics, such as antibodies, into extracellular vesicles (EVs) for therapeutic delivery is inefficient and lacks controllability, scalability, and cost-effectiveness, particularly with genetic modification methods that result in low receptor density on EVs.
Innovation Solution
The use of fusion constructs comprising human exosomal proteins fused to Fc binding polypeptides, which efficiently coat EVs with high-affinity and high-density Fc domain-containing proteins, enabling enhanced therapeutic potential through dense coating and improved targeting capabilities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If genetic modification methods are used to load protein biologics into EVs, then EVs can be produced with therapeutic proteins, but the receptor density on EVs remains low and the process lacks scalability
Solution Approach 1:
The patent introduces Fc binding proteins as intermediary molecules that bridge EVs and Fc-containing therapeutic proteins. These Fc binders are displayed on EV surfaces and specifically bind to Fc domains of therapeutic antibodies or Fc-fused proteins, enabling efficient loading without genetic modification of EV-producing cells. This intermediary approach achieves high receptor density while maintaining scalability and controllability
Solution Approach 2:
The patent replaces complex genetic modification mechanisms with a simpler biochemical binding mechanism. Instead of using transfection or electroporation to introduce therapeutic proteins into EVs, the system uses natural Fc-Fc binder interactions to attach therapeutic proteins to EV surfaces, achieving efficient loading through affinity-based binding rather than mechanical or genetic manipulation
2Reliability
If large and complex protein biologics are loaded into EVs using conventional methods, then therapeutic delivery is enabled, but the loading efficiency is poor and the process is not cost-effective
Solution Approach 1:
The patent changes the binding parameters by using high-affinity Fc-Fc binder interactions. By selecting Fc binders with optimized binding constants and displaying them at high densities on EV surfaces, the system achieves efficient capture and retention of large Fc-containing proteins. This parameter optimization enables reliable therapeutic delivery while improving loading efficiency and reducing costs through simplified purification processes
3Quantity of substance
If Fc binding proteins are displayed on EV surfaces, then high-density coating with Fc-containing proteins is achieved, but the complexity of EV production increases
Solution Approach 1:
The patent segments the EV production process into distinct functional modules: (1) EV generation from source cells, (2) expression and display of Fc binders on EV surfaces, and (3) binding of Fc-containing therapeutic proteins to Fc binders. This segmentation allows each module to be optimized independently, achieving high-density protein coating while managing production complexity through modular design and standardized protocols
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for efficient, controllable, and scalable coating of EVs with therapeutic proteins, enhancing their therapeutic efficacy by improving targeting, stability, and delivery to specific tissues and cells, including the CNS, while reducing immune-mediated clearance.
Implementation Method 1
The Fc binding polypeptide can bind an Fc domain of a protein of interest
Data Source
Figure 1
Figure 2A~2B
Figure 3A~3C
AI summary
The present invention pertains to extracellular vesicle (EV) therapeutics, wherein the EVs are coated with proteins containing Fc domains (such as antibodies) for i.a. targeting and therapeutic applications. The coating of EVs is achieved through inventive protein engineering of EV polypeptides. The present invention thus relates to methods for coating of EVs, EVs per se, as well as pharmaceutical compositions and medical applications of such EVs coated with Fc containing proteins.